Old Web
English
Sign In
Acemap
>
Paper
>
1284P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
1284P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
2021
Bo Gao
Zhiyong Ma
Xiaoguang Yu
D. Huang
Jiuran Zhao
Daphne Day
A.L. Body
Qing Zhou
Q. Chu
Hongming Pan
Jiuwei Cui
C. Chen
X. Xiang
C. Fei
L. Yang
Y-L. Wu
Keywords:
Refractory
in patient
Oncology
Internal medicine
Medicine
Sitravatinib
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]